- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
BlossomHill Therapeutics, Inc. Common Stock(BLSM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BLSM
11/13/2026: BLSM (1-star) is currently NOT-A-BUY. Pass it for now.
BlossomHill Therapeutics is a clinical-stage biopharmaceutical stock focused on designing precision small-molecule medicines for drug-resistant cancers. The company's main strengths lie in its experienced founding leadership and its differentiated macrocyclic chemistry platform targeting conditions like EGFR-mutant lung cancer. Its core growth story centres on advancing lead candidate BH-30643 toward registrational trials and expanding its innovative preclinical pipeline. Key risks include heavy pipeline concentration, intense competition from established blockbusters, and an absence of commercial revenues. The stock suits growth-oriented investors with high risk tolerance who are willing to monitor upcoming clinical data catalysts closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth potential anchored by clinical-stage oncology catalysts and a novel small-molecule pipeline. |
| Momentum investor | Strong fit while signal remains positive | Momentum appeal is closely tied to clinical data readouts, regulatory updates, and short-term biotech sector trading sentiment. |
| Value investor | Weak fit | The absence of revenues, earnings, and traditional valuation metrics makes it unsuitable for value-oriented strategies. |
| Dividend investor | Weak fit | BlossomHill pays no dividends and reinvests all capital into clinical trials. |
| Low-risk investor | Weak fit | High clinical development risk, price volatility, and regulatory uncertainty expose investors to significant capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience sharp price movements driven by clinical data updates and market sentiment. |
| Valuation risk | High | Valuations rely heavily on future clinical success and probability-adjusted commercial projections rather than current financial earnings. |
| Competition risk (oncology therapeutics) | High | The company contends with deeply entrenched pharmaceutical giants dominating standard-of-care cancer treatments. |
| Business quality | Medium | The company features specialized scientific expertise and experienced founders, though it lacks commercial maturity. |
| Dividend income | Low / none | No dividend distributions are paid or anticipated as capital funds ongoing R&D activities. |
| Execution risk | High | Success depends entirely on successfully executing clinical trials, meeting regulatory endpoints, and managing clinical burn rates. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 445.62M USD | Price to earnings Ratio - | 1Y Target Price 35.4 |
Price to earnings Ratio - | 1Y Target Price 35.4 | ||
Volume (30-day avg) 172.5K shares | Beta - | 52 Weeks Range 11.02 - 27.99 | Updated Date 11/15/2026 |
52 Weeks Range 11.02 - 27.99 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.7 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Insufficient Data
The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
The stock price exhibits a Insufficient Data stability pattern.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical-Stage Therapeutics Pipeline | Research, development, and future commercialization rights of targeted oncology medicines such as BH-30643 and BH-30236. | The company currently generates zero revenue and relies on equity funding while working to advance drug candidates toward commercial approval. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 375.21M | Price to Sales(TTM) - |
Enterprise Value 375.21M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 31.78M | Shares Floating 17.63M |
Shares Outstanding 31.78M | Shares Floating 17.63M | ||
Percent Insiders 12.71 | Percent Institutions 42.64 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

